SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Altruist Biologics, a world-class contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics (1801.HK), announced that its Suzhou commercial manufacturing facility has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the first time the facility has successfully received EMA GMP certification.

The inspection supported the European Union marketing authorization application for a biologics product from a top biopharmaceutical client. The EMA inspection involved a comprehensive assessment covering the full biologics manufacturing lifecycle and a rigorous review of the facility's quality systems and operational performance. The Suzhou facility's quality management system, infrastructure, technical capabilities, data integrity controls and organizational management were highly recognized by the EMA. The company's robust Quality Risk Management (QRM) framework has enabled proactive identification of compliance risks, reduced uncertainties associated with cross-regional technology transfer, and provided greater predictability as innovative therapies advance toward global regulatory submission and commercialization.

Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, commented: "Quality spans the entire biologics lifecycle, ensuring compliance with rigorous regulatory requirements from development through commercialization. As innovative drug companies face complex cross-border requirements, uncertainties with technology transfer, and increasing capacity needs, Altruist is committed to providing a path forward for every innovative medicine at the highest global standards. The recent EMA GMP certification exemplifies that our robust manufacturing processes, quality systems, talent and world-class facility meet regulatory requirements, and we have the agency's trust to manufacture and deliver products on behalf of our global partners and the patients they serve."

Altruist's Suzhou and Hangzhou sites are designed and operated to meet GMP requirements across multiple major regulatory authorities, including the EMA, U.S. Food and Drug Administration (FDA), the Pharmaceutical and Medical Devices Agency (PMDA) of Japan, and the National Medical Products Administration (NMPA) of China. Equipped with 60,000 liters of antibody manufacturing capacity and an ADC clinical manufacturing line, the Suzhou facility provides end-to-end services for antibodies, fusion proteins and antibody drug conjugates. The Hangzhou site is designed with a total antibody manufacturing capacity of 172,000 liters, with 80,000 liters currently operational across four 20,000-liter stainless steel bioreactors. A 2,000-liter antibody production line is currently under construction and is expected to be operational by mid-2027.

Altruist collectively has 140,000 liters of operational CDMO manufacturing capacity, representing approximately 20% of China's total capacity. As additional planned capacity comes online, Altruist's total manufacturing capacity is expected to reach 232,000 liters, positioning the company among the top 10 biologics CDMOs globally by manufacturing capacity.

In addition to the EMA, the Suzhou site has received multiple recognitions from other global regulatory authorities. It has successfully completed remote interactive evaluation by the FDA, and has passed inspections by the NMPA and the Federal Committee for Protection from Sanitary Risks (COFEPRIS) of Mexico, as well as more than 40 quality audits conducted by global clients.

Building on this milestone, Altruist Biologics is committed to providing global biotech and pharmaceutical companies with high-quality, reliable CDMO services, supporting more innovative therapies from around the world to overcome geographic and regulatory barriers to reach patients faster.

About Altruist Biologics

Altruist Biologics is a reliable CDMO service provider and wholly owned subsidiary of Innovent Biologics, Inc. (1801.HK), focusing on the development, clinical, and commercial manufacturing of antibodies, fusion proteins, recombinant proteins, antibody drug conjugates, and other drugs. The company operates advanced cGMP facilities in Suzhou and Hangzhou, China, with a total production capacity of 232,000 liters, and continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility, safety and agility for clients. With over a decade of bioprocessing expertise, the company has supported the commercialization of 20 drugs and completed more than 2,000 commercial batches with a >99.8% success rate. Its track record includes 100 global regulatory filings with the FDA, EMA, NMPA, PMDA, and TGA as well as over 80 successful regulatory authority inspections across global markets. With over 1,400 employees, including leading experts and scientists spanning all areas of biologics production and innovation, Altruist is committed to supporting clients in developing affordable and high-quality biopharmaceuticals for the benefit of patients worldwide.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/altruist-biologics-suzhou-site-receives-ema-gmp-certification-enabling-product-commercialization-for-the-european-market-302884526.html

Inflationssorgen und steigende Ölpreise haben Europas wichtigste Aktienmärkte zur Wochenmitte spürbar belastet und zugleich die Monatsbilanz eingetrübt. Der EuroStoxx 50 schloss am Mittwoch 0,81 Prozent tiefer bei 6269,02 Punkten. Im Monatsverlauf verlor der Leitindex der Eurozone 2,4 Prozent und beendete damit eine Serie von fünf Anstiegen in Folge. Der DAX gab um 0,79 Prozent auf 25.199,19 Punkte nach, während der britische FTSE moderat um rund ein Viertel Prozent auf gut 10.600 Zähler nachgab.

Treiber der Risikoaversion waren neue Inflationsdaten aus großen Euroländern. In Deutschland kletterten die Verbraucherpreise im September auf 3,3 Prozent gegenüber dem Vorjahr und damit erstmals seit Ende 2023 wieder über die Marke von drei Prozent, nachdem im August noch 2,9 Prozent verzeichnet worden waren. Starke Anstiege der Energiepreise wirkten als Hauptfaktor – eine Entwicklung, die sich nach ersten Angaben auch in Frankreich und Italien widerspiegelt. In Italien kam es zudem zu einem deutlichen Anstieg der Teuerung, was die Sorge nährte, dass der disinflationäre Trend im Euroraum ins Stocken geraten könnte.

Parallel dazu zogen die Ölpreise erneut an. Marktteilnehmer verwiesen auf die angespannte geopolitische Lage im Nahen Osten und mögliche Risiken für die Öllieferungen aus dem Persischen Golf. Berichte, wonach mehrere Tankschiffe in der Straße von Hormuz unter Beschuss geraten sein sollen, verstärkten die Nervosität. Höhere Energiekosten und im Umfeld der Inflationsdaten steigende Anleiherenditen machten Anleger nach Einschätzung von Marktstrategen europaweit selektiver. Ulrich Urbahn, Leiter Multi-Asset-Strategie und Research bei Berenberg, sieht dennoch Chancen für eine Jahresendrallye: Robuste Unternehmensgewinne könnten die Märkte stützen, sofern Firmen ihre Margen und Prognosen behaupten und sowohl Inflation als auch Renditen nicht weiter zulegen.

Im Branchenspektrum fehlten klare Impulse von den Technologiewerten, die nach Vortagesgewinnen überwiegend richtungslos tendierten. Viele Investoren warteten auf die anstehenden Quartalszahlen des US-Speicherchip-Herstellers Micron, die als Gradmesser gelten, ob der Boom rund um Künstliche Intelligenz weiterhin ausreichend im operativen Geschäft der Halbleiterbranche ankommt. Analyst Andreas Lipkow von CMC Markets warnte, eine Enttäuschung bei Micron könne die zuletzt gewachsene Skepsis gegenüber dem KI-Sektor rasch in neuen Verkaufsdruck umschlagen lassen. Einzelwerte wie BMW im DAX konnten sich diesem Umfeld zwar mit Kursgewinnen entziehen, insgesamt dominierte an den europäischen Börsen jedoch zum Monatsende die Vorsicht.